Mga Batayang Estadistika
| LEI | 5493002Q5LITR7VHZH02 |
| CIK | 1746473 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pliant Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 7, 2025 |
Pliant Therapeutics, Inc. Retention Agreement [Date] [Name] Dear [Name], In consideration of the activities necessary for Pliant Therapeutics, Inc. (“Company”) to support critical programs, the Company is offering you a cash retention award in an amount equal to [●] (the “Retention Award”). The Retention Award is subject to the terms and conditions provided below. The Retention Award will vest on |
|
| August 7, 2025 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, CA., August 7, 2025 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clini |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC |
|
| June 9, 2025 |
CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLIANT THERAPEUTICS, INC. |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
Amended and Restated Non-Employee Director Compensation Policy PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, IN |
|
| May 8, 2025 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, CA., May 8, 202 |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confi |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-4272481 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No |
|
| March 13, 2025 |
EX-4.1 Exhibit 4.1 STOCKHOLDER RIGHTS AGREEMENT Pliant Therapeutics, Inc. and Computershare Trust Company, N.A., as Rights Agent Dated as of March 12, 2025 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 10 Section 3. Issuance of Rights Certificates 10 Section 4. Form of Rights Certificates 12 Section 5. Countersignature and Registration 13 Section 6. |
|
| March 13, 2025 |
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement EX-99.1 Exhibit 99.1 Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement South San Francisco, CA—March 13, 2025 – Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement |
|
| March 13, 2025 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF PLIANT THERAPEUTICS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned hereby certifies that the following resolution was duly adopted by the board of directors of Pliant Therapeutics, Inc., a Delaware corporation (the “Corporation”), on March 12, 2025: RESO |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2025 |
PLIANT THERAPEUTICS, INC. INSIDER TRADING COMPLIANCE POLICY Pliant Therapeutics, Inc., a Delaware corporation (the “Company”) prohibits: •insider trading in the Company’s securities or stock (collectively, “Securities”); and •the unauthorized disclosure of the Company’s confidential information that might enable others to engage in insider trading in the Securities. The Company designed this Insid |
|
| March 3, 2025 |
Amended and Restated Non-Employee Director Compensation Policy PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company |
|
| March 3, 2025 |
2022 Inducement Plan dated September 14, 2022. PLIANT THERAPEUTICS, INC. 2022 INDUCEMENT PLAN 1.PURPOSE OF PLAN The purpose of this Pliant Therapeutics, Inc. 2022 Inducement Plan (this “Plan”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsidiaries as employees by affording such |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLIANT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-4272481 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) 331 Oyster Point Boulevard South San Francisco, CA 94080 (Address of Principal Ex |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 3, 2025 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, CA., March 3, 2025 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment |
|
| March 3, 2025 |
Calculation of Filing Fee Table Calculation of Filing Fee Tables S-8 PLIANT THERAPEUTICS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share Other 3,043,047 $ 3.08 $ 9,372,584.76 0.0001531 $ 1,434.94 2 Equi |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-393 |
|
| February 13, 2025 |
Exhibit 99.1 Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial data SOUTH SAN FRANCISCO, CA., February 13, 2025 - Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of th |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 10, 2025 |
Exhibit 99.1 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, CA., February 7, 2025 - Pliant Therapeutics, Inc. (Nasdaq: PLRX) today |
|
| November 14, 2024 |
EX-99.1 2 tm2427858d7ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par valu |
|
| November 14, 2024 |
EX-99.A 2 ex99-a.htm JOINT FILING AGREEMENT CUSIP No . 729139105 Page 7 of 7 Exhibit A JOINT FILING AGREEMENT The Undersigned agree that the statement on Schedule 13G with respect to the common stock of Pliant Therapeutics, Inc, dated as of November 14, 2024, is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with |
|
| November 14, 2024 |
PLRX / Pliant Therapeutics, Inc. / Blue Owl Capital Holdings LP - SC 13G/A Passive Investment SC 13G/A 1 ef20038687sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 729139 105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| November 14, 2024 |
PLRX / Pliant Therapeutics, Inc. / Redmile Group, LLC - SC 13G Passive Investment SC 13G 1 tm2427858d7sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Pliant therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 14, 2024 |
SC 13G/A 1 plrx-sc13ga093024.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment) Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 729139105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement |
|
| November 12, 2024 |
SC 13G/A 1 plrxa1111224.htm LAURION CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139105 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing |
|
| November 7, 2024 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, CA., November 7, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 4, 2024 |
EX-99.1 2 tm2424913d1ex1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Pliant Therapeutics, Inc., and furth |
|
| October 4, 2024 |
PLRX / Pliant Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 729139105 (CUSIP Number) September 24, 2024 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 27, 2024 |
THIRD AMENDED AND RESTATED BYLAWS OF PLIANT THERAPEUTICS, INC. (the “Corporation”) TABLE OF CONTENTS Page SECTION 1. Annual Meeting 1 SECTION 2. Notice of Stockholder Business and Nominations. 1 SECTION 3. Special Meetings 11 SECTION 4. Notice of Meetings; Adjournments. 12 SECTION 5. Quorum 13 SECTION 6. Voting and Proxies 13 SECTION 7. Action at Meeting 13 SECTION 8. Stockholder Lists 14 SECTION |
|
| August 7, 2024 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS-PSC 320 mg dose group demonstrated bexotegrast was well tolerated with con |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 15, 2024 |
Exhibit 99.1 Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events 320 mg cohort demons |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
EX-99.1 Exhibit 99.1 Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 6, 2024 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of March 11, 2024 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1. |
|
| May 6, 2024 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring bexotegrast’s effect on total lung collagen and FVC in IPF patients expected in the coming weeks Regulator |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, IN |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| April 22, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 12, 2024 |
Exhibit 99.1 Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis Acceptance by European Union and other global health authorities of the pivotal, adaptive Phase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt facility extends cash runway and funds accelerated development throu |
|
| February 27, 2024 |
PLIANT THERAPEUTICS, INC. POLICY ON RECOUPMENT AND FORFEITURE OF INCENTIVE COMPENSATION Adopted September 21, 2023 Overview The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Pliant Therapeutics, Inc. (the “Company”) believes it is prudent to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-per |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-393 |
|
| February 27, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Pliant Therapeutics, Inc. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 27, 2024 |
Amended and Restated Non-Employee Director Compensation Policy PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLIANT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-4272481 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification No.) 260 Littlefield Avenue, South San Francisco, CA 94080 (Address of Principal Execu |
|
| February 27, 2024 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN FRANCISCO, CA., February 27, 2024 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage |
|
| February 14, 2024 |
PLRX / Pliant Therapeutics, Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment SC 13G 1 ef20021763sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 729139 105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
PLRX / Pliant Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d8sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Pliant therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2024 |
SC 13G 1 plrxsc13g-123123.htm ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
PLRX / Pliant Therapeutics, Inc. / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d787653dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Pliant Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 729139 105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2024 |
PLRX / Pliant Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-plrx123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PLIANT THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) C |
|
| February 14, 2024 |
EX-99.1 2 tm245846d8ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par value |
|
| February 13, 2024 |
PLRX / Pliant Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01713-plianttherapeuticsin.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Pliant Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 729139105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs |
|
| February 8, 2024 |
PLRX / Pliant Therapeutics, Inc. / Laurion Capital Management LP Passive Investment SC 13G 1 laurion-plrx123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PLIANT THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2024 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 5, 2024 |
Exhibit 99.1 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS |
|
| November 9, 2023 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification Key Clinical Development and Regulatory appointments expand leadership team SOUTH SAN FRANC |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 3, 2023 |
Lease Agreement by and between the Registrant and HCP BTC, LLC, dated September 28, 2023. BRITANNIA OYSTER POINT LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between HCP BTC, LLC, a Delaware limited liability company ("Landlord"), and PLIANT THERAPEUTICS, INC. |
|
| October 3, 2023 |
TERMINATION AGREEMENT This Termination Agreement (this "Agreement") is entered into as of September 28 , 2023, by and between HEALTHPEAK OP, LLC, a Maryland limited liability company (successor-interest to HCP, Inc. |
|
| September 26, 2023 |
Exhibit 99.1 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 9, 2023 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF INTEGRIS-PSC Phase 2a 12-week data of bexotegrast in patients with PSC expected in the third quarter of 2023 Initiation of Phase 1 trial of PLN-101095 in patients with solid tumors resistant to checkpoint inhibitors |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2023 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results Positive long-term data from INTEGRIS-IPF 320 mg dose group at 24-weeks demonstrated bexotegrast was well tolerated with durable improvement shown across multiple measures INTEGRIS-PSC 12-week data expected in the third quarter of 2023 BEACON-IPF Phase 2b trial initiation expected in mid-202 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, IN |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 1, 2023 |
EX-99.1 Exhibit 99.1 Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC de |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use |
|
| April 26, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confi |
|
| March 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pliant Therapeutics, Inc. |
|
| March 27, 2023 |
As filed with the Securities and Exchange Commission on March 27, 2023 Table of Contents As filed with the Securities and Exchange Commission on March 27, 2023 Registration No. |
|
| March 20, 2023 |
PLRX / Pliant Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-393 |
|
| March 9, 2023 |
Calculation of Filing Fee Table EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Pliant Therapeutics, Inc. |
|
| March 9, 2023 |
firstamendmenttoloanands EAST\196098002.6 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of October 4, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity |
|
| March 9, 2023 |
firstamendmenttocollabor DocuSign Envelope ID: 65968F64-E079-45BD-8FC2-229D077252F8 EXECUTION COPY CONFIDENTIAL Page 1 of 6 FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This First Amendment to Collaboration and License Agreement (the “First Amendment”) is entered into as of November 15, 2022 (the “Amendment Effective Date”), by and between Pliant Therapeutics, Inc. |
|
| March 9, 2023 |
Amended and Restated Non-Employee Director Compensation Policy non-employeedirectorcomp ACTIVE/106239414.4 PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who a |
|
| March 9, 2023 |
2022 Inducement Plan dated September 14, 2022. a2022inducementplan PLIANT THERAPEUTICS, INC. 2022 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Pliant Therapeutics, Inc. 2022 Inducement Plan (this “Plan”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsidiaries as employ |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 9, 2023 |
Offer Letter, by and between the Registrant and Lily Cheung, dated December 21, 2022. offerletter-lilycheung December 21, 2022 Dear Lily: We are very pleased to offer you the position of Chief Human Resources Officer, at Pliant Therapeutics, Inc. |
|
| March 9, 2023 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results –Positive data from bexotegrast INTEGRIS-IPF 320 mg dose group demonstrated a continued favorable safety profile and statistically significant increases in FVC –INTEGRIS-IPF 320 mg dose 24-week data expected in the second quarter of 2023 –$287.5 million equity financing extends runway into |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 17, 2023 PLIANT THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2023 |
PLRX / Pliant Therapeutics Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Pliant Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 729139 105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2023 |
EX-99.1 2 tm236041d16ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 |
|
| February 14, 2023 |
PLRX / Pliant Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d16sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Pliant therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 13, 2023 |
PLRX / Pliant Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment SC 13G/A 1 plrxa221323.htm CHI ADVISORS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statem |
|
| January 25, 2023 |
EX-1.1 2 d455919dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION Pliant Therapeutics, Inc. 8,333,334 Shares Common Stock (par value $0.0001 per share) Underwriting Agreement New York, New York January 24, 2023 J.P. Morgan Securities LLC Piper Sandler & Co. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Piper Sandler & Co. |
|
| January 25, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 25, 2023 |
424B5 1 d425201d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-257684 and 333-269397 Prospectus supplement (To prospectus dated July 11, 2022) 8,333,334 shares Common stock We are offering 8,333,334 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “PLRX”. On January 24, 2023, the last reported sale |
|
| January 24, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pliant Therapeutics, Inc. |
|
| January 24, 2023 |
As filed with the Securities and Exchange Commission on January 24, 2023 As filed with the Securities and Exchange Commission on January 24, 2023 Registration No. |
|
| January 23, 2023 |
EX-99.1 Exhibit 99.1 Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegras |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 23, 2023 |
Subject to completion, dated January 23, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257684 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 9, 2023 |
EX-99.1 2 d406540dex991.htm EX-99.1 Exhibit 99.1 Developing Novel Treatments for Fibrotic Diseases JANUARY 2023 © 2023 PLIANT THERAPEUTICS Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ( we, us, our, Pliant or the “Company”). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained here |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2022 |
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results EX-99.1 2 a3q2022exhibit991.htm EX-99.1 Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results SOUTH SAN FRANCISCO, CA., November 8, 2022 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 16, 2022 |
Amended and Restated Bylaws of the Registrant, as currently in effect. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF PLIANT THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pl |
|
| August 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139 105 (CUSIP Number) August 8, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| August 31, 2022 |
EVIDENCE OF SIGNATORY AUTHORITY EXHIBIT 99.2 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis AG Identification number Legal status Entry Cancelled 1 CHE-103.867.266 Limited or Corporation 01.03.1996 All data In Ca Business name Ref Legal seat 1 Novartis AG 1 Basel 1 (Novartis SA) (Novartis Inc.) CHE-103.867.266 Novartis AG Basel 1 All data In Mo Ca Personal Data Function Signature 8 Retzler, Dr. Char |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC |
|
| August 8, 2022 |
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results SOUTH SAN FRANCISCO, CA., August 8, 2022 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial re |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 14, 2022 |
Joint book-running managers J.P. Morgan Cowen RBC Capital Markets Lead managers Cantor BTIG Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257684 Prospectus supplement (To prospectus dated July 11, 2022) 10,810,811 shares Common stock We are offering 10,810,811 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?PLRX?. On July 12, 2022, the last reported sale price of our common stock on the Nasdaq Global Se |
|
| July 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 14, 2022 |
Exhibit 1.1 EXECUTION VERSION Pliant Therapeutics, Inc. 10,810,811 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York July 12, 2022 J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New Yor |
|
| July 11, 2022 |
As filed with the Securities and Exchange Commission on July 11, 2022 As filed with the Securities and Exchange Commission on July 11, 2022 Registration No. |
|
| July 11, 2022 |
Joint book-running managers J.P. Morgan Cowen RBC Capital Markets Lead managers Cantor BTIG Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257684 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| July 11, 2022 |
Exhibit 99.1 Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment PLN-74809 treatment effect was observed on top of standard of care therapy and as monotherapy PLN-74809 was |
|
| July 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| May 27, 2022 |
SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SUITE 2000 SAN FRANCISCO, CA 94104 +1 415 772 1200 +1 415 772 7400 FAX AMERICA ? ASIA PACIFIC ? EUROPE +1 415 772 1207 CFLEMING@SIDLEY. |
|
| May 9, 2022 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results $100 million Oxford loan facility extends cash runway to mid-2024 FDA Fast Track designation granted to PLN-74809 in IPF INTEGRIS-IPF Phase 2a data readout in mid-2022 EMA Orphan Drug designation granted to PLN-74809 in PSC SOUTH SAN FRANCISCO, CA., May 9, 2022 - Pliant Therapeutics, Inc. (N |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, IN |
|
| May 5, 2022 |
Loan and Security Agreement, by and between Registrant and Oxford Finance LLC, dated May 4, 2022. Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of May 4, 2022 (the ?Effective Date?) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alex |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ??? Check the appropriate box: ?? Preliminary Proxy Statement ? |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use o |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of I |
|
| March 1, 2022 |
Calculation of Registration Fee EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Pliant Therapeutics, Inc. |
|
| March 1, 2022 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results SOUTH SAN FRANCISCO, CA., February 28, 2022 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-393 |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3 |
|
| March 1, 2022 |
Amended and Restated Non-Employee Director Compensation Policy PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Pliant Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment on Form S-3 (Form Type) Pliant Therapeutics, Inc. |
|
| February 28, 2022 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results SOUTH SAN FRANCISCO, CA., February 28, 2022 - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter |
|
| February 14, 2022 |
PLRX / Pliant Therapeutics Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pliant Therapeutics, Inc. (Name of Issuer ? as specified in its charter) Common Stock, $0.0001 par value (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of Pliant Therapeutics, |
|
| February 14, 2022 |
PLRX / Pliant Therapeutics Inc / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Pliant therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 11, 2022 |
PLRX / Pliant Therapeutics Inc / CHI Advisors LLC - CHI ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 10, 2022 |
Exhibit 99.1 Developing Novel Treatments for Fibrotic Diseases Corporate Presentation JANUARY 2022 Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the ?Company?). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of thi |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 9, 2021 |
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results SOUTH SAN FRANCISCO, CA ? November 9, 2021 - Pliant Therapeutics, Inc. (Nasdaq: PLRX) (?the Company?), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported third quarter 2 |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 7, 2021 |
Exhibit 99.1 Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis - Single dose administration of PLN-74809 achieved ?vb6 target engagement up to 98% in the lungs of IPF patients - All doses achieved target engagement above the threshold for predicted anti-fibrotic activity, with an observed dose-response relat |
|
| August 9, 2021 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results - SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed in extended Phase 1a trial of PLN-74809 in healthy volunteers with no safety concerns identified - PLN-74809 Phase 2a 12-week trials in IPF and PSC currently on track to complete enrollment by the end of 2021 and first half o |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 2, 2021 |
Exhibit 1.2 PLIANT THERAPEUTICS, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement July 2, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Pliant Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Is |
|
| July 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 2, 2021 |
Form of Senior Indenture between Pliant Therapeutics, Inc. and one or more trustees to be named Exhibit 4.9 PLIANT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certifica |
|
| July 2, 2021 |
Exhibit 4.10 PLIANT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Ce |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 2, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, IN |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2021 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results - PLN-74809 Phase 2a PET Imaging Trial Continues to Enroll with Preliminary Data Expected First Half of 2021 - PLN-74809 Phase 2a 12-week trials in IPF and PSC Currently on Track to Complete Enrollment by the End of 2021 and First Half of 2022, Respectively SOUTH SAN FRANCISCO - May 10, 2021 |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) ? INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for |
|
| April 30, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) ? INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement |
|
| March 16, 2021 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Pliant Therapeutics, Inc. (the ?Company,? ?we,? ?us,? and ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Common Stock. Description of Common Stock The following description of |
|
| March 16, 2021 |
As filed with the Securities and Exchange Commission on March 16, 2021 Registration No. |
|
| March 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39303 PLIANT THERAPEU |
|
| March 16, 2021 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results - PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021 - PLN-74809 Phase 2a 12-week trials in IPF and PSC Gained Momentum in the Fourth Quarter, Currently on Track to Complete Enrollment by the End of 2021 and First Half of 2022, Resp |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Pliant therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Pliant Therapeutics, |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Pliant Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 729139 105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 729139105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 13, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 21, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PLIANT THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pl |
|
| December 21, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (C |
|
| November 10, 2020 |
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results - Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing - Phase 2a PET imaging trial of PLN-74809 in IPF enrolling - Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers SOUTH SAN FRANCISCO ? November 10, 2020 ? Pliant Therapeu |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2020 |
Offer Letter, by and between the Registrant and Mike Ouimette, dated August 17, 2020. Exhibit 10.1 August 12, 2020 Dear Mike: We are very pleased to offer you the position of General Counsel & Corporate Secretary, at Pliant Therapeutics, Inc., a Delaware corporation (the ?Company?), with an employment commencement date by October 1, 2020. This letter outlines certain terms and conditions of your employment with the Company. We would be delighted to answer any questions you may have |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC. |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020. PLIANT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39303 47-4272481 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 11, 2020 |
Amended and Restated Bylaws of the Registrant, as currently in effect. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PLIANT THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1.Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may |
|
| August 11, 2020 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLIANT THERAPEUTICS, INC. Pliant Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is Pliant Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on |
|
| August 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39303 PLIANT THERAPEUTICS, INC. |
|
| August 11, 2020 |
Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Announces Second-Quarter 2020 Financial Results -Raised over $175 million in initial public offering and concurrent private placement to advance lead product candidate PLN-74809 for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis -Continued progress of Phase 2a 12-week trials of IPF and PSC with sites |
|
| June 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Pliant Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 729139 105 (CUSIP Number) June 5, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 15, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock of Pliant Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall b |
|
| June 9, 2020 |
PLRX / Pliant Therapeutics, Inc. / Redmile Group, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) PLIANT THERAPEUTICS, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 729139 105 (CUSIP Number) June 5, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| June 9, 2020 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Pliant Therapeutics, |
|
| June 4, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 3, 2020 Registration No. |
|
| June 3, 2020 |
9,000,000 Shares Pliant Therapeutics, Inc. Common Stock $16.00 per share 424B4 Table of Contents File pursuant to Rule 424(b)(4) Registration No. 333-238146 9,000,000 Shares Pliant Therapeutics, Inc. Common Stock $16.00 per share This is the initial public offering of our common stock. We are selling 9,000,000 shares of common stock. Prior to this offering there has been no public market for our shares. The initial public offering price is $16.00 per share of common st |
|
| June 2, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 2, 2020 Registration No. |
|
| May 29, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Pliant Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4272481 (State of incorporation or organization) (I.R.S. Employer Identification No.) 260 Littlef |
|
| May 29, 2020 |
CORRESP VIA EDGAR May 29, 2020 Office of Life Science Division of Corporation Finance U. |
|
| May 29, 2020 |
CORRESP May 29, 2020 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N. |
|
| May 26, 2020 |
CORRESP Goodwin Procter LLP Three Embarcadero Center, 28th Floor San Francisco, CA 94111 goodwinlaw. |
|
| May 26, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF PLIANT THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pl |
|
| May 26, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on May 26, 2020 Registration No. |
|
| May 26, 2020 |
2020 Employee Stock Purchase Plan. EX-10.3 Exhibit 10.3 PLIANT THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Pliant Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Pliant Therapeutics, Inc. (the “Company”) and each Designated Company with opportunities to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). 70 |
|
| May 26, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLIANT THERAPEUTICS, INC. Pliant Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Pliant Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporatio |
|
| May 26, 2020 |
EX-10.2 Exhibit 10.2 PLIANT THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Pliant Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Pliant Therapeutics, Inc. (the “Company”) |
|
| May 26, 2020 |
Specimen Common Stock Certificate EX-4.1 Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PAR VALUE $0.0001 Certificate Shares Number * * 000000 ****************** * * * 000000 ***************** ZQ00000000 **** 000000 **************** PLIANT THERAPEUTICS, INC. ***** 000000 *************** ****** 000000 ************** INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander Davi |
|
| May 26, 2020 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLIANT THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Pliant Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DO |
|
| May 26, 2020 |
Non-Employee Director Compensation Policy. EX-10.6 Exhibit 10.6 PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or off |
|
| May 26, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 Pliant Therapeutics, Inc. [●] Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York [●], 2020 Citigroup Global Markets Inc. Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Cowen and Company, LLC 599 Lexington Avenue New York, N |
|
| May 13, 2020 |
CORRESP Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 CONFIDENTIAL TREATMENT REQUESTED BY PLIANT THERAPEUTICS, INC. CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED IN THIS LETTE |
|
| May 11, 2020 |
Prior Non-Employee Director Compensation Policy. EX-10.5 Exhibit 10.5 Amended and Restated Non-Employee Director Compensation Policy This Amended and Restated Non-Employee Director Compensation Policy applies to non-employee directors, other than the chairperson or lead director, who are not affiliated with major investors. Subject to Board approval, the Company shall grant you, as a non-employee director of the Company, an option to purchase 18 |
|
| May 11, 2020 |
Senior Executive Cash Incentive Bonus Plan. EX-10.4 Exhibit 10.4 PLIANT THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Pliant Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals |
|
| May 11, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2020 Registration No. |
|
| May 11, 2020 |
EX-4.2 Exhibit 4.2 Execution Version PLIANT THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 19, 2019 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of December, 2019, by and among PLIANT THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the inves |
|
| May 11, 2020 |
Offer Letter, by and between the Registrant and Barbara Howes, dated May 1, 2019. EX-10.12 Exhibit 10.12 April 26, 2019 Dear Barbara Howes: We are very pleased to offer you the position of Chief Human Resources Officer, at Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), with an employment commencement date by May 1, 2019. This letter outlines certain terms and conditions of your employment with the Company. We would be delighted to answer any questions you ma |
|
| May 11, 2020 |
Offer Letter, by and between the Registrant and Éric Lefebvre, M.D., dated February 28, 2018. EX-10.11 Exhibit 10.11 700 Saginaw Drive, Suite 150 Redwood City, CA 94063 February 27, 2018 Eric A. Lefebvre, M.D. Re: Employment Offer Dear Eric: Pliant Therapeutics, Inc. (“Pliant” or the “Company”) is pleased to confirm its offer to employ you as Chief Medical Officer. You will report to the Company’s Chief Executive Officer, Bernard Coulie. Your effective date of hire as a regular, full time |
|
| May 11, 2020 |
EX-10.13 Exhibit 10.13 PLIANT THERAPEUTICS, INC. [FORM OF] DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [] by and between Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), and [] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, t |
|
| May 11, 2020 |
Offer Letter, by and between the Registrant and Hans Hull, J.D., dated February 10, 2016. EX-10.9 Exhibit 10.9 700 Saginaw Drive, Suite 150 Redwood City, CA 94063 February 9, 2016 Hans Hull San Francisco, CA 94110 EMAIL: Re: Employment Offer Dear Hans, Pliant Therapeutics, Inc. (“Pliant” or the “Company”) is pleased to confirm its offer to employ you as Chief Business Officer. As Chief Business Officer, you will report to the Company’s Chief Executive Officer, Bernard Coulie. Your effe |
|
| May 11, 2020 |
EX-10.15 Exhibit 10.15 EXECUTION COPY CONFIDENTIAL COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. AND PLIANT THERAPEUTICS, INC. COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (this "Agreement") is made as of October 17, 2019 (the "Execution Date"), by and between Novartis Institutes for Biomedical Research, Inc., a |
|
| May 11, 2020 |
2015 Equity Incentive Plan and forms of award agreements thereunder. EX-10.1 Exhibit 10.1 PLIANT THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: August 19, 2015 APPROVED BY THE STOCKHOLDERS: August 19, 2015 TERMINATION DATE: August 18, 2025 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of the foll |
|
| May 11, 2020 |
Non-Employee Director Compensation Policy. EX-10.6 Exhibit 10.6 PLIANT THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or off |
|
| May 11, 2020 |
EX-10.14 Exhibit 10.14 EDGEWATER BUSINESS PARK LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP, INC., a Maryland corporation (“Landlord”), and PLIANT THERAPEUTICS, INC., a Delaware corporation (“Tenant”). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION 1. Date: Feb |
|
| May 11, 2020 |
Offer Letter, by and between the Registrant and Keith Cummings, M.D., MBA, dated November 29, 2018. EX-10.10 Exhibit 10.10 November 21, 2018 Dear Keith: Position. We are very pleased to offer you the position of Chief Financial Officer of Pliant Therapeutics, Inc., a Delaware corporation (the “Company”), with an employment commencement date of not later than December 31, 2018. You will have the normal duties, responsibilities and authority of an executive serving in the position of Chief Financi |
|
| May 11, 2020 |
EX-10.7 Exhibit 10.7 PLIANT THERAPEUTICS, INC. EXECUTIVE SEVERANCE PLAN 1. Purpose. Pliant Therapeutics, Inc., a Delaware corporation (the “Company”) considers it essential to the best interests of its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly-held co |
|
| May 11, 2020 |
Offer Letter, by and between the Registrant and Bernard Coulie, M.D., Ph.D., dated October 12, 2015. EX-10.8 Exhibit 10.8 Pliant Therapeutics 700 Saginaw Drive Suite 150 Redwood City, CA 94063 Oct 7th, 2015 Bernard Coulie, MD, Ph.D. BY EMAIL: Grimdestraat 23 B-3000 Leuven BELGIUM Re: Employment Offer Pliant Therapeutics Dear Bernard: Pliant Therapeutics, Inc. (“Pliant” or the “Company”) is pleased to confirm its offer to employ you. Your effective date of hire as a regular, full time employee (th |
|
| May 11, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PLIANT THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) PLIANT THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: |
